In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">⁠Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://de.linkedin.com/in/regina-hodits-270a7481" target="_blank">Regina Hodits</a>, Managing Director, Angelini Ventures<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/sofia-ioannidou-1410748/" target="_blank">Sofia Ioannidou</a>, VC Partner, Andera Life SciencesDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.